{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:37:56Z","timestamp":1787330276353,"version":"build-2736575974"},"reference-count":36,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/03007995.2026.2665022","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:58:02Z","timestamp":1779285482000},"page":"473-485","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Comparative economic analysis of B-cell maturation antigen-targeted bispecific antibodies in triple-class exposed relapsed\/refractory multiple myeloma: linvoseltamab versus teclistamab and elranatamab"],"prefix":"10.1080","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-4078","authenticated-orcid":false,"given":"Timothy J.","family":"Inocencio","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-9366","authenticated-orcid":false,"given":"Peter","family":"Quon","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4217-0118","authenticated-orcid":false,"given":"James","family":"Harnett","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-8479","authenticated-orcid":false,"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-6525","authenticated-orcid":false,"given":"Nisha C.","family":"Hazra","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-8740","authenticated-orcid":false,"given":"Michael K.","family":"Xu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Eales","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hekun","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-7543","authenticated-orcid":false,"given":"Michelle","family":"Little","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-3487","authenticated-orcid":false,"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1641196"},{"key":"e_1_3_6_3_1","unstructured":"Surveillance Epidemiology and End Results Program (SEER). Cancer Stat Facts: Myeloma 2024 [cited 2024 Oct 7]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_6_6_1","unstructured":"Food and Drug Administration. LYNOZYFIC\u2122 (linvoseltamab-gcpt) Prescribing information. 2025. Regeneron Pharmaceuticals Inc.; Tarrytown (NY) [cited 2025 Jul]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761400s000lbl.pdf."},{"key":"e_1_3_6_7_1","unstructured":"European Medicines Agency. LYNOZYFIC\u2122 (linvoseltamab-gcpt) Summary of Product Characteristics. 2025. Regeneron Pharmaceuticals Inc.; Tarrytown (NY) [cited 2025 Sep]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynozyfic-epar-product-information_en.pdf."},{"key":"e_1_3_6_8_1","unstructured":"Food and Drug Administration. TECVAYLI\u00ae (teclistamab-cqyv) Prescribing information. 2024. Janssen Biotech; Horsham (PA) [cited 2024 May]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761291s008lbl.pdf."},{"key":"e_1_3_6_9_1","unstructured":"European Medicines Agency. TECVAYLI\u00ae (teclistamab-cqyv) Summary of Product Characteristics. 2024. Janssen Biotech; Horsham (PA) [cited 2025 Sep]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf."},{"key":"e_1_3_6_10_1","unstructured":"Food and Drug Administration. 2023. ELREXFIO\u00ae (elranatamab) Prescribing information. Pfizer; New York (NY) [cited 2025 Jul]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761345s003lbl.pdf."},{"key":"e_1_3_6_11_1","unstructured":"European Medicines Agency. 2023. ELREXFIO\u00ae (elranatamab) Summary of Product Characteristics. 2023. Pfizer; New York (NY) [cited 2025 Sep]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.014"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7531"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/jbm.S507550"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070467"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.03.013"},{"key":"e_1_3_6_21_1","unstructured":"Merative. Micromedex\u00ae RED BOOK\u00ae [Internet] [cited 2026 Feb]. Available from: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00228-5"},{"key":"e_1_3_6_23_1","unstructured":"American Hospital Association (AHA). Trendwatch Chartbook 2021: Trends affecting hospitals and health systems. [Internet]; 2021 [cited 2024 Oct 11]. Available from: https:\/\/www.aha.org\/system\/files\/media\/file\/2022\/11\/2021-Trendwatch-Chartbook-PDF.pdf."},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003531"},{"key":"e_1_3_6_25_1","unstructured":"Agency for Healthcare Research and Quality (AHRQ). Healthcare cost and utilization project (HCUP) [Internet]; 2021 [cited 2024 Apr]. Available from: https:\/\/hcup-us.ahrq.gov\/."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00198-0"},{"key":"e_1_3_6_27_1","first-page":"13","volume-title":"Proceedings of the 29th European Hematology Association Congress","author":"Weisel KC","year":"2024","unstructured":"Weisel KC, Kumar S, Ma Q, et al. Comparative effectiveness of linvoseltamab versus standard-of-care treatment in real-world patients in the United States with triple-class exposed relapsed\/refractory multiple myelomaProceedings of the 29th European Hematology Association Congress. Madrid, Spain; 2024 June 13\u201316."},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000469"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S501404"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30559-3"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0061"},{"key":"e_1_3_6_33_1","volume-title":"Clinical Laboratory Fee Schedule. CY 2024 Q4 Release: added for October 2024 [Internet]","author":"Centers for Medicare and Medicaid Services (CMS)","year":"2025","unstructured":"Centers for Medicare and Medicaid Services (CMS). Clinical Laboratory Fee Schedule. CY 2024 Q4 Release: added for October 2024 [Internet]. Baltimore (MD): U.S. Centers for Medicare & Medicaid Services; 2025 [cited 2025 Feb]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs\/files\/24clabq4."},{"key":"e_1_3_6_34_1","volume-title":"Physician Fee Schedule 2024 [Internet]","author":"Centers for Medicare and Medicaid Services (CMS)","year":"2024","unstructured":"Centers for Medicare and Medicaid Services (CMS). Physician Fee Schedule 2024 [Internet]. Baltimore (MD): U.S. Centers for Medicare & Medicaid Services; 2024 [cited 2025 Feb]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"e_1_3_6_35_1","volume-title":"Commercial reimbursement benchmarking [Internet]","author":"Anderson C","year":"2023","unstructured":"Anderson C, Mills C, Zhou D. Commercial reimbursement benchmarking [Internet]. Seattle, WA: Milliman; 2023 [cited 2025 Jul]. Available from: https:\/\/www.milliman.com\/en\/insight\/commercial-reimbursement-benchmarking-payment-rates-medicare-fee-for-service."},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2514909"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2665022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/03007995.2026.2665022","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2665022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:55:13Z","timestamp":1787327713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2026.2665022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/03007995.2026.2665022"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2026.2665022","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}